Skip to main content
Mavrik Dental

About Mavrik

Mavrik Dental Systems Ltd®., is a privately held company with proprietary technology for the dental in-office treatment market. The guiding principle for Mavrik is to automate dental therapies in an effort to improve efficiency, procedural efficacy, patient experience, and return OTC solutions to professional care. The first product is a profound advancement in the area of Tooth Whitening. Mavrik’s Thera-Smile™ solution is the first fully automated system that will provide the clinician unparalleled efficiency and outcomes. Mavrik is a blend of Israeli technology with US Sales & Marketing leadership, fusing proficiency and commercial expertise.

The Company’s Founders, Board of Directors, and CEO have extensive industry experience, providing a real world perspective on delivering premier patient care.

Mavrik Leadership

Tom Olsen

Tom Olsen
CEO

Tom Olsen / Tom Olsen
CEO

Mr. Olsen has more than 35 years of executive experience in the dental industry, with a strong track record of proven results and leadership, strategic market development, and organizational expertise.

Prior to joining Mavrik Dental Systems, Mr. Olsen served for 26 years at Nobel Biocare where he held leadership positions in the Europe, APAC and LATAM markets. Since 2011 he led the North American business for Nobel Biocare as President and General Manager with consistent growth and market share gains while maintaining the leading market position.

Mr. Olsen serves on the Board of the American College of Prosthodontist Education Foundation and the Boston University Henry M. Goldman School of Dental Medicine Deans Advisory Board.

Dr. Daniel Sanders BS DDS

Dr. Daniel Sanders BS DDS
Founder, Director & Global CMO

Dr. Daniel Sanders BS DDS / Dr. Daniel Sanders BS DDS
Founder, Director & Global CMO

A graduate of the Columbia University College of Dental Medicine in New York, Dr. Sanders has advanced training in dental trauma and surgery. Dr. Sanders has done extensive research and testing for Clinician’s Report and maintained a high-end private dental practice in Mid-Manhattan for 20 years. Dr. Sanders holds over 40 international patents on numerous dental devices.

Dr. Morris Strauss BDS Dip. Orth

Dr. Morris Strauss BDS Dip. Orth
Founder, Director

Dr. Morris Strauss BDS Dip. Orth / Dr. Morris Strauss BDS Dip. Orth
Founder, Director

A graduate of the University of the Witwatersrand, received his orthodontic degree from Tel Aviv University Dental School (class of 1976) and is a clinical instructor in its post-graduate orthodontic department for over three decades. Dr. Strauss maintains a cutting edge private orthodontics practice in Herzliya, Israel. Dr. Strauss holds a patent on an innovative orthodontic device.

Dan Even

Dan Even
Chairman of the Board

Dan Even / Dan Even
Chairman of the Board

Dan has more than 30 years of progressive leadership with Sybron Dental Specialties as well as sitting on several VC backed boards. As CEO of Sybron Dental, the company surpassed $1B in Revenue, achieved consistent earnings growth and completed a successful transaction with Danaher (NYSE:DHR).

Frank Yu

Frank Yu
Director

Frank Yu / Frank Yu
Director

Mr. Yu is the founder, CEO and CIO of Ally Bridge Group, a leading global life science-dedicated investment group. Mr. Yu carries a strong track record as an investment manager across multiple funds and strategies with investments in the U.S., China and Europe. Mr. Yu started his career in New York, then worked in Hong Kong for over two decades. Previously, Mr. Yu was Managing Director and Head of China Investments at Och-Ziff Capital Management (OZ), a leading global hedge fund, where he made some of OZ’s largest and highly successful investments. Prior to OZ, Mr. Yu was a Managing Director at Goldman Sachs in Hong Kong, where he headed several business units and played instrumental roles in some of the most important restructuring, IPO and M&A transactions of leading Chinese companies. Mr. Yu also advised leading global institutions on their China and Asia strategies and transactions. Before Goldman Sachs, Mr. Yu worked at Moody’s in New York, and then Credit Suisse in London and Hong Kong.

Since 2010, Mr. Yu has founded, launched and managed 7 funds covering venture, growth, buyout and hedge fund investing from China to U.S. to Europe. Mr. Yu excels in originating and executing major investment themes such as global life science investing, which has become the primary focus of Mr. Yu and Ally Bridge, creating high-impact deals such as the landmark US$3.3 billion WuXi Pharmatech. He has expertise in cementing strategic transactions between emerging players and industry leaders across the U.S., China and Europe.

Charlie Chon

Charlie Chon
Director

Charlie Chon / Charlie Chon
Director

Charles Chon is a Partner and Managing Director of Ally Bridge Group. Mr. Chon leads ABG’s Medical Technologies effort and is a member of ABG’s Investment Committee. Before joining ABG in 2013, Mr. Chon had been a healthcare public equity research analyst for over 13 years on both buy-side and sell-side, mostly as Vice President and senior equity research analyst at Goldman Sachs on the US medical devices team. From there, Mr. Chon became the Sector Head for US medical devices research at Stifel Nicolaus. Mr. Chon began his career on Wall Street at ABN AMRO and also covered the healthcare sector from the buy-side at Fred Alger Management. Mr. Chon holds CFA designation, and received his MBA in healthcare management from Boston University and BA in Chemistry from Amherst College.

CEO / Tom Olsen

Mr. Olsen has more than 35 years of executive experience in the dental industry, with a strong track record of proven results and leadership, strategic market development, and organizational expertise.

Prior to joining Mavrik Dental Systems, Mr. Olsen served for 26 years at Nobel Biocare where he held leadership positions in the Europe, APAC and LATAM markets. Since 2011 he led the North American business for Nobel Biocare as President and General Manager with consistent growth and market share gains while maintaining the leading market position.

Mr. Olsen serves on the Board of the American College of Prosthodontist Education Foundation and the Boston University Henry M. Goldman School of Dental Medicine Deans Advisory Board.

Founder, Director & Global CMO / Dr. Daniel Sanders BS DDS

A graduate of the Columbia University College of Dental Medicine in New York, Dr. Sanders has advanced training in dental trauma and surgery. Dr. Sanders has done extensive research and testing for Clinician’s Report and maintained a high-end private dental practice in Mid-Manhattan for 20 years. Dr. Sanders holds over 40 international patents on numerous dental devices.

Founder, Director / Dr. Morris Strauss BDS Dip. Orth

A graduate of the University of the Witwatersrand, received his orthodontic degree from Tel Aviv University Dental School (class of 1976) and is a clinical instructor in its post-graduate orthodontic department for over three decades. Dr. Strauss maintains a cutting edge private orthodontics practice in Herzliya, Israel. Dr. Strauss holds a patent on an innovative orthodontic device.

Chairman of the Board / Dan Even

Dan has more than 30 years of progressive leadership with Sybron Dental Specialties as well as sitting on several VC backed boards. As CEO of Sybron Dental, the company surpassed $1B in Revenue, achieved consistent earnings growth and completed a successful transaction with Danaher (NYSE:DHR).

Director / Frank Yu

Mr. Yu is the founder, CEO and CIO of Ally Bridge Group, a leading global life science-dedicated investment group. Mr. Yu carries a strong track record as an investment manager across multiple funds and strategies with investments in the U.S., China and Europe. Mr. Yu started his career in New York, then worked in Hong Kong for over two decades. Previously, Mr. Yu was Managing Director and Head of China Investments at Och-Ziff Capital Management (OZ), a leading global hedge fund, where he made some of OZ’s largest and highly successful investments. Prior to OZ, Mr. Yu was a Managing Director at Goldman Sachs in Hong Kong, where he headed several business units and played instrumental roles in some of the most important restructuring, IPO and M&A transactions of leading Chinese companies. Mr. Yu also advised leading global institutions on their China and Asia strategies and transactions. Before Goldman Sachs, Mr. Yu worked at Moody’s in New York, and then Credit Suisse in London and Hong Kong.

Since 2010, Mr. Yu has founded, launched and managed 7 funds covering venture, growth, buyout and hedge fund investing from China to U.S. to Europe. Mr. Yu excels in originating and executing major investment themes such as global life science investing, which has become the primary focus of Mr. Yu and Ally Bridge, creating high-impact deals such as the landmark US$3.3 billion WuXi Pharmatech. He has expertise in cementing strategic transactions between emerging players and industry leaders across the U.S., China and Europe.

Director / Charlie Chon

Charles Chon is a Partner and Managing Director of Ally Bridge Group. Mr. Chon leads ABG’s Medical Technologies effort and is a member of ABG’s Investment Committee. Before joining ABG in 2013, Mr. Chon had been a healthcare public equity research analyst for over 13 years on both buy-side and sell-side, mostly as Vice President and senior equity research analyst at Goldman Sachs on the US medical devices team. From there, Mr. Chon became the Sector Head for US medical devices research at Stifel Nicolaus. Mr. Chon began his career on Wall Street at ABN AMRO and also covered the healthcare sector from the buy-side at Fred Alger Management. Mr. Chon holds CFA designation, and received his MBA in healthcare management from Boston University and BA in Chemistry from Amherst College.